Homoharringtonine/omacetaxine mepesuccinate: the long and winding road to food and drug administration approval.

  title={Homoharringtonine/omacetaxine mepesuccinate: the long and winding road to food and drug administration approval.},
  author={Hagop M Kantarjian and Susan O'brien and Jorge E. Cortes},
  journal={Clinical lymphoma, myeloma & leukemia},
  volume={13 5},
Homoharringtonine/omacetaxine is a unique agent with a long history of research development. It has been recently approved by the Food and Drug Administration for the treatment of chronic myeloid leukemia after failure of 2 or more tyrosine kinase inhibitors. Research with this agent has spanned over 40 years, with many instructive lessons to cancer research, which are summarized in this review. 
11 Citations
40 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 11 extracted citations


Publications referenced by this paper.
Showing 1-10 of 40 references

The first semi-synthesis of enantiopure homoharringtonine via anhydrohomoharringtonine from a preformed chiral acyl moiety

  • J Robin, R Dhal, G Dujardin
  • Tetrahedron Lett
  • 1999
Highly Influential
5 Excerpts

Homoharringtonine-based induction regimens for patients with de novo acute myeloid leukemia: a multicenter randomized controlled phase 3 trial

  • J Jin, J Wang, F Chen
  • Blood
  • 2012
2 Excerpts

Subcutaneous omacetaxine in chronic or accelerated chronic myeloid leukemia resistant to two or more tyrosine-kinase inhibitors including imatinib

  • J Cortes, F Nicollini, M Wetzler
  • Blood
  • 2011
1 Excerpt

Similar Papers

Loading similar papers…